BACKGROUND Anthracyclines and taxanes are more active group of chemotherapy regimen.Randomized controlled trials(RCTs) reported variable evidences regarding efficacy of taxanes over anthracyclines for tumor response a...BACKGROUND Anthracyclines and taxanes are more active group of chemotherapy regimen.Randomized controlled trials(RCTs) reported variable evidences regarding efficacy of taxanes over anthracyclines for tumor response and survival outcomes. The present study compares the relative efficacy of taxanes over anthracyclines using pathological complete response(pCR), clinical responses,breast-conserving surgeries and survival outcomes in female breast cancer patients by systematic review and meta-analysis of available RCTs.AIM To assess the effectiveness of taxanes over anthracyclines in neoadjuvant setting in terms of tumor response and survival outcomes.METHODS All RCTs assessing efficacy of taxanes over anthracyclines in neoadjuvant setting for management of breast cancer searched through PubMed and Cochrane register of controlled trials on 28 April 2017 and published in English language were considered. Following PRISMA guideline, retrieved records were screened and data were extracted by two independent reviewers. Meta-analysis was performed using fixed effect or random effect method depending on heterogeneity assessed using I^2 statistic. Subgroup meta-analyses on the basis of taxane alone or taxane along with anthracycline in comparison to anthracycline alone were also performed for each considered outcomes.RESULTS A total of 16 RCTs involving 6752 breast cancer patients were found eligible.Taxanes based chemotherapy significantly improved pCR(n = 7, RR = 1.48,95%CI: 1.04-2.12), disease free survival [n = 6, RR = 0.89(0.80-0.99)] and locoregional recurrence free survival [n = 4, RR = 0.74(0.59-0.94)]. Interestingly in subgroup analysis, addition of taxane to anthracyclines showed better effectiveness regarding these survivals over anthracyclines than taxane alone over anthracycline.CONCLUSION Addition of taxanes to anthracyclines based chemotherapy significantly improves pCR, disease free survival and loco-regional recurrence free survival but with no significant impact on breast conservation rates.展开更多
文摘BACKGROUND Anthracyclines and taxanes are more active group of chemotherapy regimen.Randomized controlled trials(RCTs) reported variable evidences regarding efficacy of taxanes over anthracyclines for tumor response and survival outcomes. The present study compares the relative efficacy of taxanes over anthracyclines using pathological complete response(pCR), clinical responses,breast-conserving surgeries and survival outcomes in female breast cancer patients by systematic review and meta-analysis of available RCTs.AIM To assess the effectiveness of taxanes over anthracyclines in neoadjuvant setting in terms of tumor response and survival outcomes.METHODS All RCTs assessing efficacy of taxanes over anthracyclines in neoadjuvant setting for management of breast cancer searched through PubMed and Cochrane register of controlled trials on 28 April 2017 and published in English language were considered. Following PRISMA guideline, retrieved records were screened and data were extracted by two independent reviewers. Meta-analysis was performed using fixed effect or random effect method depending on heterogeneity assessed using I^2 statistic. Subgroup meta-analyses on the basis of taxane alone or taxane along with anthracycline in comparison to anthracycline alone were also performed for each considered outcomes.RESULTS A total of 16 RCTs involving 6752 breast cancer patients were found eligible.Taxanes based chemotherapy significantly improved pCR(n = 7, RR = 1.48,95%CI: 1.04-2.12), disease free survival [n = 6, RR = 0.89(0.80-0.99)] and locoregional recurrence free survival [n = 4, RR = 0.74(0.59-0.94)]. Interestingly in subgroup analysis, addition of taxane to anthracyclines showed better effectiveness regarding these survivals over anthracyclines than taxane alone over anthracycline.CONCLUSION Addition of taxanes to anthracyclines based chemotherapy significantly improves pCR, disease free survival and loco-regional recurrence free survival but with no significant impact on breast conservation rates.
